Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis.
To determine whether serum immunity to Porphyromonas gingivalis peptidylarginine deiminase (PPAD) affects the clinical response to biological disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA).In a retrospective study, rheumatologic and periodontal conditions of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4844134?pdf=render |
| _version_ | 1818675184368877568 |
|---|---|
| author | Tetsuo Kobayashi Satoshi Ito Daisuke Kobayashi Atsushi Shimada Ichiei Narita Akira Murasawa Kiyoshi Nakazono Hiromasa Yoshie |
| author_facet | Tetsuo Kobayashi Satoshi Ito Daisuke Kobayashi Atsushi Shimada Ichiei Narita Akira Murasawa Kiyoshi Nakazono Hiromasa Yoshie |
| author_sort | Tetsuo Kobayashi |
| collection | DOAJ |
| description | To determine whether serum immunity to Porphyromonas gingivalis peptidylarginine deiminase (PPAD) affects the clinical response to biological disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA).In a retrospective study, rheumatologic and periodontal conditions of 60 patients with RA who had been treated with conventional synthetic DMARD were evaluated before (baseline) and after 3 and 6 months of bDMARD therapy. After serum levels of anti-PPAD immunoglobulin G (IgG) were determined at baseline, the patients were respectively divided into two groups for high and low anti-PPAD IgG titers according to the median measurements. Genotypes at 8 functional single nucleotide polymorphisms (SNPs) related to RA were also determined.After 3 and 6 months of therapy, patients with low anti-PPAD IgG titers showed a significantly greater decrease in changes in the Disease Activity Score including 28 joints using C-reactive protein (DAS28-CRP) (P = 0.04 for both) and anti-cyclic citrullinated peptide (CCP) IgG levels (P = 0.03 and P = 0.04) than patients with high anti-PPAD IgG titers, although these parameter values were comparable at baseline. The anti-PPAD IgG titers were significantly positively correlated with changes in the DAS28-CRP (P = 0.01 for both) and the anti-CCP IgG levels (P = 0.02 for both) from baseline to 3 and 6 months later. A multiple regression analysis revealed a significantly positive association between the anti-PPAD IgG titers and changes in the DAS28-CRP after 6 months of bDMARD therapy (P = 0.006), after adjusting for age, gender, smoking, periodontal condition, and RA-related SNPs.The serum IgG levels to PPAD affect the clinical response to bDMARD in patients with RA. |
| first_indexed | 2024-12-17T08:23:33Z |
| format | Article |
| id | doaj.art-7715dc038d3a4e859c227d41eebc3315 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-17T08:23:33Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7715dc038d3a4e859c227d41eebc33152022-12-21T21:56:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01114e015418210.1371/journal.pone.0154182Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis.Tetsuo KobayashiSatoshi ItoDaisuke KobayashiAtsushi ShimadaIchiei NaritaAkira MurasawaKiyoshi NakazonoHiromasa YoshieTo determine whether serum immunity to Porphyromonas gingivalis peptidylarginine deiminase (PPAD) affects the clinical response to biological disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA).In a retrospective study, rheumatologic and periodontal conditions of 60 patients with RA who had been treated with conventional synthetic DMARD were evaluated before (baseline) and after 3 and 6 months of bDMARD therapy. After serum levels of anti-PPAD immunoglobulin G (IgG) were determined at baseline, the patients were respectively divided into two groups for high and low anti-PPAD IgG titers according to the median measurements. Genotypes at 8 functional single nucleotide polymorphisms (SNPs) related to RA were also determined.After 3 and 6 months of therapy, patients with low anti-PPAD IgG titers showed a significantly greater decrease in changes in the Disease Activity Score including 28 joints using C-reactive protein (DAS28-CRP) (P = 0.04 for both) and anti-cyclic citrullinated peptide (CCP) IgG levels (P = 0.03 and P = 0.04) than patients with high anti-PPAD IgG titers, although these parameter values were comparable at baseline. The anti-PPAD IgG titers were significantly positively correlated with changes in the DAS28-CRP (P = 0.01 for both) and the anti-CCP IgG levels (P = 0.02 for both) from baseline to 3 and 6 months later. A multiple regression analysis revealed a significantly positive association between the anti-PPAD IgG titers and changes in the DAS28-CRP after 6 months of bDMARD therapy (P = 0.006), after adjusting for age, gender, smoking, periodontal condition, and RA-related SNPs.The serum IgG levels to PPAD affect the clinical response to bDMARD in patients with RA.http://europepmc.org/articles/PMC4844134?pdf=render |
| spellingShingle | Tetsuo Kobayashi Satoshi Ito Daisuke Kobayashi Atsushi Shimada Ichiei Narita Akira Murasawa Kiyoshi Nakazono Hiromasa Yoshie Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis. PLoS ONE |
| title | Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis. |
| title_full | Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis. |
| title_fullStr | Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis. |
| title_full_unstemmed | Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis. |
| title_short | Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis. |
| title_sort | serum immunoglobulin g levels to porphyromonas gingivalis peptidylarginine deiminase affect clinical response to biological disease modifying antirheumatic drug in rheumatoid arthritis |
| url | http://europepmc.org/articles/PMC4844134?pdf=render |
| work_keys_str_mv | AT tetsuokobayashi serumimmunoglobulinglevelstoporphyromonasgingivalispeptidylargininedeiminaseaffectclinicalresponsetobiologicaldiseasemodifyingantirheumaticdruginrheumatoidarthritis AT satoshiito serumimmunoglobulinglevelstoporphyromonasgingivalispeptidylargininedeiminaseaffectclinicalresponsetobiologicaldiseasemodifyingantirheumaticdruginrheumatoidarthritis AT daisukekobayashi serumimmunoglobulinglevelstoporphyromonasgingivalispeptidylargininedeiminaseaffectclinicalresponsetobiologicaldiseasemodifyingantirheumaticdruginrheumatoidarthritis AT atsushishimada serumimmunoglobulinglevelstoporphyromonasgingivalispeptidylargininedeiminaseaffectclinicalresponsetobiologicaldiseasemodifyingantirheumaticdruginrheumatoidarthritis AT ichieinarita serumimmunoglobulinglevelstoporphyromonasgingivalispeptidylargininedeiminaseaffectclinicalresponsetobiologicaldiseasemodifyingantirheumaticdruginrheumatoidarthritis AT akiramurasawa serumimmunoglobulinglevelstoporphyromonasgingivalispeptidylargininedeiminaseaffectclinicalresponsetobiologicaldiseasemodifyingantirheumaticdruginrheumatoidarthritis AT kiyoshinakazono serumimmunoglobulinglevelstoporphyromonasgingivalispeptidylargininedeiminaseaffectclinicalresponsetobiologicaldiseasemodifyingantirheumaticdruginrheumatoidarthritis AT hiromasayoshie serumimmunoglobulinglevelstoporphyromonasgingivalispeptidylargininedeiminaseaffectclinicalresponsetobiologicaldiseasemodifyingantirheumaticdruginrheumatoidarthritis |